Side-by-side comparison of AI visibility scores, market position, and capabilities
NYC YC W20 MSK Cancer Center spinout with FDA Breakthrough Device for whole-genome/transcriptome tumor profiling; $5M total (Two Sigma/NCI SBIR) competing with Foundation Medicine and Tempus AI for comprehensive genomic profiling in pediatric and rare cancers.
Isabl is a New York-based whole-genome and transcriptome cancer diagnostics company — backed by Y Combinator (W20) with $5 million in total funding including $3 million from Two Sigma Ventures, BoxOne Ventures, Bossa Invest, and Jude Gomilla, plus a $2 million SBIR grant from the National Cancer Institute (NCI) — commercializing the Isabl GxT (Genome x Transcriptome) diagnostic platform that received FDA Breakthrough Device Designation for comprehensive tumor profiling that analyzes entire tumor genomes and transcriptomes simultaneously to identify cancer-associated mutations, fusion genes, and expression patterns that guide treatment selection. Founded in 2020 after incubating at Memorial Sloan Kettering Cancer Center (MSKCC) from 2015-2019, Isabl's genomic testing platform is specifically advancing through March 2025 NCI funding for pediatric and rare solid cancers where comprehensive genomic profiling can identify targeted therapy opportunities that standard panel tests miss.
SF AI healthcare administration automating medical coding, billing, and claims for clinics with 30% cost savings and 20% fewer denials; YC S23 $4.5M competing with Waystar for revenue cycle management automation.
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Graphene Ventures, and Orange Collective — providing medical clinics and healthcare providers with autonomous AI agents that handle medical coding, billing, claims submission, denial management, scheduling coordination, and patient payment collection, automating 80%+ of the repetitive administrative tasks that currently consume 30-40% of healthcare provider revenue in overhead costs. Founded in 2023 by Daniyal Afzal, James Oswald, and Kevin Cheng, Decoda's AI agents deliver 30% reduction in coding costs, 20% reduction in claim denials, and claims processing in seconds versus the days that manual coding and submission require.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.